Solvay Develops Industry-First Specialized UV-C Stabilizers for the Protection of Polyolefin Surfaces

Solvay, a global market leader in specialty materials, has announced the development of an innovative new portfolio of UV-C stabilizers. They are designed for use in demanding hygiene applications, where polyolefin surfaces are treated with ultra-violet (UV) light of the UV-C spectrum (200-280 nm) to fight against COVID and hospital-acquired infections.

The new proprietary stabilization technology represents an important milestone for the polyolefin industry, as it is the first to address the risk of polyolefin degradation, discoloration and micro-crack formation, which is caused by frequent exposure to UV-C irradiation.

“Healthcare and other markets, such as aerospace and shared mobility, are increasingly using UV-C light to disinfect high-contact surfaces in an effort to combat pathogens, including coronaviruses,” says Sophie Poelmans, Global Marketing Manager for Polymer Additives at Solvay Materials. “Our new UV-C stabilization technology helps end-users achieve effective UV-C disinfection levels on surfaces made from polyolefins without compromising the performance of the material.”

UV-C radiation can deactivate microorganisms and has been scientifically proven to be effective against coronaviruses. However, the proven germicidal action of UV-C also exposes the treated surfaces to much higher ultraviolet energy than that covered by traditional UV-A and UV-B stabilizers, resulting in the potential for faster material degradation.

Solvay, a member of the International Ultraviolet Association (IUVA), has leveraged its extensive expertise in polymer additives to develop a technology that is purpose-engineered to enable the use of UV-C light as an anti-microbial disinfectant on polyolefin surfaces, while safely protecting them against UV-C induced degradation.

Solvay’s new UV-C stabilization technology is targeted at a wide range of polyolefin applications, including medical equipment in operation and patient rooms, aircraft and shared vehicle interiors, and sporting venues.

SourceSolvay

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version